ACAD vs LQDA
ACADIA Pharmaceuticals Inc. vs Liquidia Corporation — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
LQDA
Liquidia Corporation
68
Buy
| Metric | ACAD | LQDA |
|---|
| AI Score |
69
|
68
|
| Price |
$29.41
|
$88.09
|
| P/E Ratio |
13.07×
|
368.26×
|
| ROE |
31.9%
|
-154.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
91.8%
|
| Debt / Equity |
0.06×
|
1.70×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
78.4
|
55.0
|
| Beta |
0.845
|
0.572
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ACAD versus LQDA.
ACAD leads by 1 points.
ACAD scores 69/100 (Buy) versus LQDA at 68/100 (Buy).
ACAD Committee View
83% agreement
6 analysts
The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.
Bull Case
- P/E of 13.2 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- RSI at 78 is in overbought territory — Technical
- Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 24.3% signals elevated volatility — Risk
LQDA Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 46.8% shows genuine earnings power backing the valuation — Value
- Revenue growing 1936.7% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 362.9 is expensive by classic value standards — Value
- Price-to-book of 12.9x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical